NeuroVive decides on a Rights issue for continued drug development
Lund, Sweden, 15 February 2018, NeuroVive Pharmaceutical AB (publ) (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces that the Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or "the Company") on 15 February 2018 resolved, subject to approval by the Extraordinary General Meeting, to issue shares and warrants with preferential rights for existing shareholders ("Rights issue"). Upon full subscription to the Rights issue, the Company will receive approximately MSEK 78.5 before issuance costs. In full exercise of the warrants issued in the Rights issue, the Company will receive